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Abstract
Introduction: Despite the benefits of endocrine therapies such as tamoxifen and aromatase inhibitors in treating
estrogen receptor (ER) alpha-positive breast cancer, many tumors eventually become resistant. The molecular
mechanisms governing resistance remain largely unknown. Pigment epithelium-derived factor (PEDF) is a
multifunctional secreted glycoprotein that displays broad anti-tumor activity based on dual targeting of the tumor
microenvironment (anti-angiogenic action) and the tumor cells (direct anti-tumor action). Recent studies indicate
that PEDF expression is significantly reduced in several tumor types, including breast cancer, and that its reduction
is associated with disease progression and poor patient outcome. In the current study, we investigated the role of
PEDF in the development of endocrine resistance in breast cancer.
Methods: PEDF mRNA and protein levels were measured in several endocrine-resistant breast cancer cell lines
including MCF-7:5C, MCF-7:2A, and BT474 and in endocrine-sensitive cell lines MCF-7, T47D, and ZR-75-1 using real-
time PCR and western blot analyses. Tissue microarray analysis and immunohistochemistry were used to assess the
PEDF protein level in tamoxifen-resistant breast tumors versus primary tumors. Lentiviruses were used to stably
express PEDF in endocrine-resistant breast cancer cell lines to determine their sensitivity to tamoxifen following
PEDF re-expression.
Results: We found that PEDF mRNA and protein levels were dramatically reduced in endocrine-resistant MCF-7:5C,
MCF-7:2A, and BT474 breast cancer cells compared with endocrine-sensitive MCF-7, T47D, and ZR-75-1 cells, and that
loss of PEDF was associated with enhanced expression of pSer167ERa and the receptor tyrosine kinase rearranged during
transfection (RET). Importantly, we found that silencing endogenous PEDF in tamoxifen-sensitive MCF-7 and T47D
breast cancer cells conferred tamoxifen resistance whereas re-expression of PEDF in endocrine-resistant MCF-7:5C and
MCF-7:2A cells restored their sensitivity to tamoxifen in vitro and in vivo through suppression of RET. Lastly, tissue
microarray studies revealed that PEDF protein was reduced in ~52.4% of recurrence tumors (31 out of 59 samples) and
loss of PEDF was associated with disease progression and poor patient outcome.
Conclusion: Overall, these findings suggest that PEDF silencing might be a novel mechanism for the development of
endocrine resistance in breast cancer and that PEDF expression might be a predictive marker of endocrine sensitivity.
Introduction
The female hormone estrogen has long been recognized
as being important for stimulating the growth of a large
proportion of breast cancers. Estrogen action is mediated
by two receptors; estrogen receptor (ER) alpha and ER
beta. Approximately 70% of breast cancers express ERa
[1,2], and its presence in breast tumors is routinely used
to predict a response to endocrine therapy such as
tamoxifen - an anti-estrogen that blocks estrogen-stimu-
lated breast cancer cell growth - or aromatase inhibitors
(AIs) - agents that suppress estrogen synthesis in the
body. These agents are highly effective and are less toxic
compared with chemotherapy, and are often offered to
ER-positive breast cancer patients to sustain a better
quality of life [3,4]. Despite the clinical benefits of tamox-
ifen and AIs, however, a large number of breast cancer
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patients develop drug resistance. It is estimated that
~40% of patients with early ER-positive breast cancer
relapse within 15 years after adjuvant therapy with
tamoxifen and 15% of patients treated with an AI relapse
within 9 years [5-7]. These resistant tumors are usually
more aggressive and are more likely to metastasize,
which is often the leading cause of breast cancer-related
death. There is strong evidence that endocrine resistance
is associated with cross-talk between upstream kinases
and ERa, resulting in estrogen-independent activation of
the ERa; however, the exact mechanism by which breast
cancer cells develop resistance to endocrine therapy is
still not fully understood.
Pigment epithelium-derived factor (PEDF) is a 50 kDa
glycoprotein that belongs to the non-inhibitory serine pro-
tease inhibitor superfamily but it does not inhibit proteases
[8,9]. PEDF was first discovered as a factor secreted by ret-
inal pigment epithelial cells [10], but was later found to be
expressed in several tissues including the brain, spinal
cord, eye, plasma, bone, prostate, pancreas, heart and lung
[11]. PEDF is present in human blood at a concentration
of approximately 100 nM (5 μg/ml) or twice the level
required to inhibit aberrant blood-vessel growth in the eye
[10]. PEDF possesses potent anti-angiogenic activity, far
greater than any other known anti-angiogenic factor [12],
and it has anti-tumor properties including the ability to
promote tumor differentiation and initiate apoptosis
[13-16]. In endothelial cells, PEDF has been shown to
induce apoptosis by activating the Fas/Fas-L caspase-8
apoptotic pathway [17,18] and there is evidence that the
p38 mitogen-activated protein kinase (MAPK) pathway is
involved in the anti-angiogenic activity of PEDF [19].
More recently, a number of studies have reported that
PEDF expression is significantly reduced in several tumor
types, including prostate adenocarcinoma [20], pancreatic
adenocarcinoma [21], glioblastoma [22], ovarian carci-
noma [23], and breast cancer [24]. With regards to breast
cancer, PEDF expression has been shown to be markedly
reduced in breast tumors compared with normal tissue
and this reduction is associated with disease progression
and poor patient outcome [24,25]. At present, however, it
is not known whether PEDF plays a role in the develop-
ment of endocrine resistance.
In this study, we examined the role of PEDF in the
development of endocrine resistance using several breast
cancer cell lines. Specifically, we evaluated PEDF expres-
sion in endocrine-resistant MCF-7:5C, MCF-7:2A, and
BT474 breast cancer cells versus endocrine-sensitive
MCF-7, T47D, and ZR-75-1 cells and found that PEDF
mRNA and protein levels were dramatically reduced in
the endocrine-resistant breast cancer cell lines compared
with the endocrine-sensitive cell lines. In addition, tissue
microarray studies revealed that PEDF protein was signif-
icantly reduced in tamoxifen-resistant/recurrence tumors
compared with primary tumors. We also found that
re-expression of PEDF in endocrine-resistant MCF-7:5C
and BT474 cells restored their sensitivity to tamoxifen,
whereas siRNA knockdown of PEDF in MCF-7 and
T47D cells markedly reduced their sensitivity to tamoxi-
fen. Notably, re-expression of PEDF in endocrine-resis-
tant MCF-7:5C cells resulted in a significant reduction in
the level of p-ERa, p-AKT, and rearranged during trans-
fection (RET) proteins, which were constitutively overex-
pressed in these cells. Lastly, we found that recombinant
PEDF (rPEDF) dramatically reduced the tumor growth of
MCF-7:5C xenographs in athymic mice and that re-
expression of PEDF in MCF-7:5C cells partially restored
tamoxifen sensitivity in vivo. Taken together, these find-
ings suggest that PEDF silencing might be a novel
mechanism for the development of endocrine resistance
in breast cancer.
Materials and methods
Cell lines and culture conditions
The MCF-7 cells used in this study [26] were cloned
from ERa-positive human MCF-7 breast cancer cells ori-
ginally obtained from the American Type Culture Collec-
tion (Manassas, VA, USA). MCF-7 cells were maintained
in full serum medium composed of RPMI-1640 medium,
10% fetal bovine serum, 2 mM glutamine, penicillin at
100 U/ml, streptomycin at 100 μg/ml, 1× nonessential
amino acids (Invitrogen, Grand Island, NY, USA), and
bovine insulin at 6 ng/ml (Sigma-Aldrich, St Louis, MO,
USA). ER-positive MCF-7:5C [27,28] and MCF-7:2A
[29,30] breast cancer cells were cloned from MCF-7 cells
following long-term (> 12 months) culture in estrogen-
free medium composed of phenol red-free RPMI, 10%
fetal bovine serum treated three times with dextran-coated
charcoal, 2 mM glutamine, bovine insulin at 6 ng/ml,
penicillin at 100 U/ml, streptomycin at 100 μg/ml, and 1×
nonessential amino acids. MCF-7:5C cells are resistant to
AIs (that is, hormone independent) and tamoxifen, but
these cells undergo apoptosis in the presence of physiolo-
gic concentrations of 17b-estradiol (E2), as previously
reported [28]. MCF-7:2A cells are also resistant to AIs but
only partially sensitive to tamoxifen, and these cells
undergo apoptosis in the presence of E2 [29,31].
The human breast cancer cell line T47D:A18, referred to
as T47D in this study, is a hormone-responsive clone of
wild-type T47D that has been described previously [32].
These cells were maintained in phenol red-containing
RPMI medium supplemented with 10% fetal bovine serum
(FBS), bovine insulin (6 ng/ml), and antibiotics. ER-posi-
tive ZR-75-1 and BT474 breast cancer cells were obtained
from the American Type Culture Collection and were
maintained in phenol red-containing RPMI medium sup-
plemented with 10% FBS, bovine insulin (6 ng/ml), and
antibiotics. The BT474 cell line was isolated by Lasfargues
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and Coutinho from a solid, invasive ductal carcinoma of
the breast [33]. ER-negative MDA-MB-231 breast cancer
cells were obtained from the American Type Culture Col-
lection and were cultured in DMEM medium supplemen-
ted with 10% FBS and antibiotics.
MCF-7:5C cells stably expressing PEDF (5C-PEDF) were
grown in phenol red-free RPMI 1640 medium supplemen-
ted with 10% phenol red-free RPMI, 10% fetal bovine
serum treated three times with dextran-coated charcoal
and 4 μg/ml blasticidin (InvivoGen, San Diego, CA, USA),
and BT474 cells stably expressing PEDF (BT474-PEDF)
were grown in RPMI medium supplemented with 10%
FBS and 4 μg/ml blasticidin (InvivoGen, San Diego, CA,
USA).
Cell proliferation assay
This procedure has been described previously [28,29,34].
Briefly, MCF-7 and T47D cells were grown in fully estro-
genized medium. Cells were seeded in 24-well plates
(30,000/well) and after overnight incubation were trans-
fected with either control (nontarget) or PEDF siRNA.
Transfected cells were treated with 10-6 M 4-hydroxyta-
moxifen (4OHT) after 48 hours, and then cells were har-
vested after 72 hours and total DNA was determined
using a Fluorescent DNA Quantitation kit (Bio-Rad
Laboratories, Hercules, CA, USA), as previously described
[28]. Cell proliferation was also determined by cell count-
ing using the trypan blue exclusion assay. MCF-7 and
T47D cells were seeded in six-well plates (1 × 105/well)
and then treated with 10-6 M 4OHT for 72 hours. The
4OHT used in the cell proliferation studies was purchased
from Sigma-Aldrich.
We also performed proliferation studies using MCF-
7:5C, BT474, 5C-PEDF, and BT474-PEDF cells. MCF-
7:5C and 5C-PEDF cells were grown in non-estrogenized
media, and BT474 and BT474-PEDF cells were grown in
fully estrogenized media. For the DNA proliferation
assay, cells were seeded at a density of 30,000/well in 24-
well plates and after overnight incubation were treated
with 10-12 M to 10-6 M 4OHT for 7 days with retreat-
ment on alternate days. Cells were then harvested and
total DNA quantitated using a Fluorescent DNA kit as
described previously [28]. For cell counting, cells were
seeded at 75,000/well in six-well plates and after over-
night incubation were treated with 10-6 M 4OHT for
72 hours. Cells were then harvested and counted using
trypan blue exclusion.
Western blot analysis
Immunoblotting was performed using 30 μg protein per
well as described previously [28,35]. Membranes were
probed with primary antibodies against PEDF (Chemicon
Inc., Temecula, CA., USA), against ERa and phospho-
Ser167-ERa (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), against RET, p-RET (Y1062), mammalian tar-
get of rapamycin (mTOR), p-mTOR and AKT, and
against pAKT, MAPK, pMAPK and p70S6K (Cell Signal-
ing Technology Inc., Danvers, MA, USA), and against b-
actin (Sigma Chemical Co., St Louis, MO, USA). The
appropriate secondary antibody conjugated to horserad-
ish peroxidase (Santa Cruz Biotechnology) was used to
visualize the stained bands with an enhanced chemilumi-
nescence visualization kit (Amersham, Arlington Heights,
IL, USA). Bands were quantitated by densitometry using
the Molecular Dynamics Software ImageQuant (GE
Healthcare Life Sciences, Piscataway, NJ, USA) and den-
sitometric values were corrected for loading control.
Knockdown of PEDF and RET with small interference RNA
For the iRNA silencing experiments, PEDF, RET, and non-
target control siRNAs were purchased from Dharmacon
Inc (Pittsburg, PA, USA). For transfection, 100 nM siRNAs
were combined with siRNA transfection reagent according
to the manufacturer’s instructions. Cells were seeded in
24-well plates at a density of 0.5 × 105 cells/well in antibio-
tics-free medium 12 hours before the transfection. One
and a half microliters of the siRNA (20 μM) were mixed
with 1 μl transfection reagent in 50 μl serum-free RPMI-
1640 medium and were incubated at room temperature
for 25 minutes to form a complex. After washing cells
with PBS, the 50 μl transfection mixtures were added to
each well with 450 μl RPMI-1640 medium containing 10%
FBS at a final concentration of 100 nM siRNA. Twenty-
four hours after the transfection, the medium was replaced
with fresh 500 μl RPMI-1640 medium containing 10%
FBS. Transfected cells were then harvested for western
blotting and RT-PCR or subsequently treated with 10-9 M
to 10-6 M 4OHT for 3 days to determine cell growth.
RNA isolation and RT-PCR analysis
Total RNA was isolated from cultured cells using the TRI-
zol reagent (Invitrogen) according to the manufacturer’s
procedure. First-strand cDNA synthesis was performed
from 2.5 μg total RNA using Super-Script Reverse Tran-
scriptase (Invitrogen). cDNA was amplified in a 15-μl PCR
mixture containing 1 mm dNTPs, 1× PCR buffer, 2.5 mm
MgCl2, and 1 U DNA Taq polymerase (Promega, Madi-
son, WI, USA) with 25 pmol of primers specific for
human PEDF (sense, 5’-CATTCACCGGGCTCTCTAC-3’;
antisense, 5’-GGCAGCTGGGCAATCTTGCA-3’) and
human RET (sense, 5’-GGATTTCGGCTTGTCCCGAG-
3’; antisense, 5’-CCATGTGGAAGG GAGGGCTC-3’).
The conditions in the logarithmic phase of PCR amplifica-
tion were as follows: 5 minutes initial denaturation at
94°C, 1 minute denaturation at 94°C, 35 seconds annealing
at 67°C, and 1.5 minute extension at 72°C for 30 cycles.
The number of amplification cycles during which PCR pro-
duct formation was limited by the template concentration
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was determined in pilot experiments. PUM1 was used as
the internal control (sense, 5’-TCACCGAGGCCCCTCT-
GAACCCTA-3’; antisense, 5’-GGCAGTAATC TCCTTCT
GCATCCT-3’).
The reproducibility of the quantitative measurements
was evaluated by three independent cDNA syntheses
and PCR amplification from each preparation of RNA.
Densitometric analysis was performed using Scion
Image software (Scion Corp., Frederick, MD, USA), and
the relative PEDF or RET mRNA expression levels were
determined as the ratio of the signal intensity of PEDF
to that of PUM1.
Estrogen response element luciferase assay
To determine ERa transcriptional activity, cells were
transfected with an estrogen response element (ERE)-regu-
lated (pERE(5×)TA-ffLuc plus pTA-srLuc) dual-luciferase
reporter gene set. pERE(5×)-ffLuc contained five copies of
a consensus ERE and a TATA-box driving firefly lucifer-
ase; pTATA-srLuc contained a TATA-box element driv-
ing renilla luciferase. Cells were grown in the estrogen-free
medium containing no exogenous compounds for 2 days
before transfection. All transfection experiments were car-
ried-out using LT1 (Mirus Bio LLC, Madison, WI, USA)
at a 1:3 ratio of micrograms of plasmid to micoliters of
LT1. In the ERE reporter gene experiment, the cells were
treated as indicated 24 hours following the transfection.
Forty-eight hours following the ERE transfection, the cells
were harvested and processed for dual-luciferase reporter
activity (Promega, Madison, WI, USA), in which the firefly
luciferase activity was normalized by renilla luciferase
activity.
Breast cancer tissue microarray and
immunohistochemistry
Paraffin-embedded de-identified human breast cancer tis-
sue samples were collected from the Tumor Bank facility
at the Fox Chase Cancer Center and the protocols were
reviewed and approved by the Institutional Review Board
at our institution. The archived tumor samples were
obtained from patients who were initially treated with
tamoxifen and either responded (n = 150) or responded
but then developed recurrence disease (n = 59) with an
average time to disease progression of 93 months. Patients
provided written informed consent for the use of their
tumor samples.
Tissue microarray slides were constructed from 59
matching primary and recurrence tumors using duplicate
cores of 0.6 mm per tumor sample. Tissue microarray
slides were also created using endocrine-responsive
tumors. For PEDF and ERa immunohistochemistry, sec-
tions were incubated at room temperature for 20 minutes
with anti-PEDF or anti-ERa antibody (Chemicon Inc.)
applied at 1:100 dilution in antibody diluent (Dako USA,
Carpinteria, CA, USA). A secondary anti-mouse antibody
polymer conjugated with horseradish peroxidase (Dako
USA) was applied for 30 minutes and 3,3’-diaminobenzi-
dine was used to produce visible, localized staining view-
able with light microscopy. Sections without primary
antibody served as negative controls. Normal breast tissue
from archival specimens was used as positive controls for
PEDF and ERa expression. A semi-automated quantitative
image analysis system (ACIS II; ChromaVision Medical
Systems, Inc., San Juan Capistrano, CA, USA) was used to
quantitate the staining of the tissue microarray slides. For
immunohistochemical analysis, the brown stain intensity
of the chromogen was compared with the blue counter-
stain used as background. Staining for PEDF was quanti-
fied as an intensity score (scale 0 to 255) and staining for
ERa was graded as follows: 0, negative (no cells stained);
1, weakly positive (< 10% of cells stained); 2, moderately
positive (10 to 50% of cells stained); or 3, strongly positive
(> 50% cells stained).
TUNEL staining for apoptosis
Apoptosis was determined by the terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end-labeling
(TUNEL) assay using an in situ cell death detection kit
(POD; Roche Molecular Biochemicals, Branchburg, NJ,
USA), according to the manufacturer’s instructions.
Briefly, fixed cells were washed, permeabilized, and then
incubated with 50 μl terminal deoxynucleotidyl transferase
end-labeling cocktail for 60 minutes at 37°C in a humidi-
fied atmosphere in the dark. For signal conversion, slides
were incubated with 50 μl converter-POD (anti-fluores-
cein antibody conjugated with horseradish peroxidase) for
30 minutes at 37°C, rinsed with PBS, and then incubated
with 50 μl of 3,3’-diaminobenzidine substrate solution for
10 minutes at 25°C. The slides were then rinsed with PBS,
mounted under glass coverslips, and analyzed under a
light microscope (Inverted Nikon TE300; Melville, NY,
USA).
Lentiviral vector design, production, and transduction
For PEDF overexpression, we generated a lentiviral con-
struct encoding the full-length human PEDF cDNA
inserted between XbaI and BamHI sites of the prrl.CMV.
EGFP.wpre.SIN lentiviral vector. Briefly, PEDF cDNA was
amplified by PCR from pCEP4-PEDF plasmid (a gift from
Dr Bouck, Northwestern University, Chicago, IL, USA);
XbaI and XbaI + EcoRV sites were added to the 5’ and 3’
ends, respectively, using primers 5’-CTAGTCTAGAG
GCCCCAGGATGCAGGC CCTG-3’ and 5’-GGCCTC
TAGATATCTTAGGGGCCCCTGGGGTCCAG-3’. This
fragment was then subcloned into TA cloning vector
(Invitrogen, San Diego, CA, USA), digested with EcoRV
and XbaI and re-cloned in the prrl.CMV.EGFP.wpre.SIN
plasmid digested with XbaI and BamHI. To produce
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lentiviral stock, 293FT cells (Invitrogen) were plated in
10-cm tissue culture plates. When the cells were 90 to
95% confluent, the complete culture medium was removed
and the cells were exposed to 5 ml medium (Opti-MEM I;
Invitrogen) with complexes (DNA-Lipofectamine 2000;
Invitrogen) containing 9 μg packaging mix (ViralPower;
Invitrogen), 3 μg expression plasmid DNA (prrl.CMV.
EGFP.wpre.SIN/PEDF), or control plasmid DNA (prrl.
CMV.EGFP.wpre.SIN/LacZ) with lipofectamine (Lipo-
fectamine 2000; Invitrogen). Hexadimethrine bromide
(Polybrene; Sigma-Aldrich) was added at the final concen-
tration of 10 μg/ml. After incubation for 24 hours, the
infection medium was replaced with complete culture
medium. Lentivirus-containing supernatants were har-
vested 72 hours after transfection. The supernatants were
centrifuged to remove pellet debris and stored at -80°C.
For lentiviral vector transduction, MCF-7:5C and BT474
cells were plated in six-well plates. When the cells reached
30 to 50% confluence, media were changed to either phe-
nol red-free RPMI medium with 10% charcoal-stripped
FBS without antibiotic (MCF-7:5C cells) or complete
growth medium without antibiotic (BT474 cells) with the
lentiviral stock, and 10 μg/ml hexadimethrine bromide
(Polybrene; Sigma-Aldrich) was added to improve lenti-
viral vector transduction. Lentiviral vector expressing lacZ
served as a positive control. After overnight incubation at
37°C in 5% CO2, the media-containing virus was removed
and replaced with 2 ml complete culture media. After
incubation overnight at 37°C in 5% CO2, media were
changed to phenol red-free RPMI medium with 10% char-
coal-stripped FBS without antibiotic or respective media
with 4 μg/ml blasticidin (InvivoGen). Transduced cell
clones were then selected with antibiotic for 2 weeks.
PEDF expression was verified by quantitative real-time
RT-PCR and western blot analysis in MCF-7:5C and
BT474 cells.
Animal studies
The mammary fat pads of 6-week-old to 8-week-old ovar-
iectomized outbred athymic mice (Taconic, Upstate, NY,
USA) were bilaterally inoculated with 5 × 106 MCF-7:5C
cells suspended in 0.1 ml sterile PBS solution as described
previously [28]. When tumors reached a mean cross-sec-
tional area of 0.1 cm2, the mice were randomized into
groups of 10 and were treated with sterile PBS (100 μl) or
4 mg/kg rPEDF that was administered by intraperitoneal
injection for a total of 30 days. Mice were injected every
2 days and tumors were measured every 5 days with ver-
nier calipers. The mean cross-sectional tumor area was
calculated by multiplying the length (l) by the width (w)
by π and dividing the product by four (that is, lwπ/4). The
mean cross-sectional tumor area was plotted against time
in days to monitor tumor growth. The mice were sacri-
ficed by CO2 inhalation and cervical dislocation; tumors
were excised and immediately fixed in 10% buffered for-
malin for immunohistochemistry or snap-frozen in liquid
nitrogen. Frozen tumor specimens were stored at -80°C
for further analysis.
In another experiment, a total of 96 ovariectomized
outbred athymic mice, 6 to 8 weeks old, were bilaterally
inoculated with 5 × 106 MCF-7, BT474, or MCF-7:5C
breast cancer cells suspended in 0.1 ml sterile PBS. Mice
injected with MCF-7 (n = 32) or BT474 cells (n = 32)
were simultaneously treated with E2 to stimulate tumor
growth. E2 was administered via 0.3 cm long silastic cap-
sules (Innovative Research, Sarasota, FL, USA) that were
implanted subcutaneously between the scapules. The cap-
sules remained in place for the duration of the study (3 to
6 weeks). Mice injected with MCF-7:5C cells (n = 32),
however, did not require treatment with E2 because these
cells are estrogen independent and are capable of forming
tumors in the absence of E2, as reported previously [28].
When the mean tumor cross-sectional area reached
approximately 0.3 cm2 for MCF-7 and BT474-injected
mice and 0.2 cm2 for MCF-7:5C-injected mice, groups of
eight mice were randomly assigned to the following treat-
ments: PBS alone (control), rPEDF, tamoxifen, or tamoxi-
fen plus rPEDF. Tamoxifen was administered orally by
gavage at 1.5 mg/day per mouse for 5 days/week for 21
days and rPEDF was administered by intraperitoneal injec-
tion at 4 mg/kg every 2 days for 21 days. Tumors were
measured weekly with vernier calipers. The mean cross-
sectional tumor area was calculated by multiplying the
length (l) by the width (w) and by π and dividing by 4
(that is, lwπ/4).
All animal experiments were carried out according to
the guidelines of the American Association for Labora-
tory Animal Science as an approved protocol by the
Institutional Animal Care and Use Committee at the
Institute for Cancer Research-Fox Chase Cancer
Center.
Microvessel density assay
Frozen tissues were cut into 10-μm sections, fixed in acet-
one at 4°C for 5 minutes, and blocked for endogenous per-
oxidase. Sections were treated with normal serum for 10
minutes. Tumor sections were incubated with the rat
monoclonal antibody against mouse CD34 (BD Pharmin-
gen, San Diego, CA, USA) at 1:100 dilutions at 4°C. After
rinsing with PBS, sections were incubated with biotiny-
lated rabbit antigoat immunoglobulins (Dako, Glostrup,
Denmark) at 1:1,000 dilutions for 30 minutes at room
temperature followed by incubation with horseradish per-
oxidase-labeled streptavidin-biotin complex for 30 min-
utes. The peroxidase reaction was visualized using
diaminobenzidine. The tumor microvessel density was
quantified as tumor vasculature. In negative-control stain-
ing, the primary antibodies were omitted.
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Statistical analysis
All in vitro experiments were repeated at least twice in
either duplicate or triplicate with different cell prepara-
tions to ensure consistency of the findings. One-factor
analysis of variance was used to demonstrate that there
were significant differences between conditions when
there were more than two conditions, and paired analyses
were performed using either Student’s t test or the
Mann-Whitney test (GraphPad Software, San Diego, CA,
USA) in order to identify the conditions that were signifi-
cantly different. For in vivo studies, tumor growth curves
were analyzed longitudinally using a two-factor analysis
of variance comparing tumor cross-sectional areas within
treatments in a time-dependent manner. Tumor growth
curves represent the mean ± standard error of tumor
cross-sectional areas. P < 0.05 was considered statistically
significant.
Results
PEDF expression is dramatically reduced in endocrine-
resistant breast cancer cells
To determine whether there is an association between
PEDF expression and endocrine resistance, we first exam-
ined PEDF expression in a panel of breast cancer cell lines
using western blot and real-time PCR analyses. We found
that PEDF protein (Figure 1a) and mRNA (Figure 1b)
levels were dramatically reduced in endocrine-resistant
MCF-7:5C, MCF-7:2A, and BT474 breast cancer cells
compared with endocrine-sensitive MCF-7, T47D, and
ZR-75-1 cells with no PEDF observed in ER-negative
MDA-MB-231 cells. A similar trend was observed when
the media conditioned by these cells were tested for PEDF
expression. As shown in Figure 1c, endocrine-sensitive
T47D, ZR-75-1 and, to a lesser extent, MCF-7 cells
secreted the most PEDF, whereas endocrine-resistant
MCF-7:5C, MCF-7:2A, and BT474 cells secreted markedly
less to no detectable level of PEDF. Interestingly, we found
that tamoxifen-resistant BT474 cells expressed a level of
PEDF almost comparable with that of MCF-7 cells
whereas AI-resistant MCF-7:5C and MCF-7:2A cells
expressed very little to no PEDF. We should note that
there are differences between BT474 cells and long-term
estrogen-deprived MCF-7:5C and MCF-7:2A cells. Specifi-
cally, BT474 cells overexpress HER2 and the ER coactiva-
tor AIB1, which contribute to tamoxifen resistance in
these cells [36], whereas MCF-7:5C and MCF-7:2A cells
express low levels of HER2 and AIB1 but high levels of
phospho-Akt and ERa, which are thought to contribute to
the AI-resistant and tamoxifen-resistant phenotype of
these cells. Tamoxifen resistance has been studied by sev-
eral groups [37,38] and is believed to be due primarily to
crosstalk between ER and HER2. This crosstalk leads to
enhanced cell survival pathways via phosphoinositide 3-
kinase (PI3K)/AKT activation in addition to activation of
various MAPKs that mediate transcriptional effects result-
ing in cell proliferation. In contrast, studies using long-
term estrogen-deprived breast cancer cells have shown
that AI resistance is controlled by several signaling path-
ways including the P13K/AKT pathway, the insulin-like
growth factor receptor (IGF-1R) pathway, and the HER2
pathway [39-41]. In addition, we have previously shown
that AI-resistant MCF-7:5C and MCF-7:2A cells undergo
apoptosis in the presence of physiological concentrations
of E2 [28,29,42]. The differences in PEDF expression
between BT474, MCF-7:5C, and MCF-7:2A cells might
possibly be influenced by the different signaling pathways
that control the resistant phenotype of these cells.
The ERa protein level was also examined in the differ-
ent cell lines to assess whether there was a correlation
between ERa status and PEDF expression. Figure 1a
showed that ERa protein was expressed in all of the cell
lines except for MDA-MB-231 cells, which are ERa-
negative; however, ERa was significantly elevated in
endocrine-resistant MCF-7:5C, MCF-7:2A, and BT474
cells compared with endocrine-sensitive MCF-7, T47D,
and ZR-75-1 cells. In addition, we found that E2 treat-
ment markedly reduced the PEDF protein level in MCF-7
and T47D cells whereas 4OHT, the active metabolite of
tamoxifen, significantly increased the PEDF protein level
in both cell lines (Figure 1d). A similar trend was
observed for ERa regulation by E2 and 4OHT in MCF-7
and T47D cells (Figure 1d). Overall, these data show that
PEDF expression is significantly reduced in endocrine-
resistant breast cancer cells compared with endocrine-
sensitive cells and that its expression is differentially
regulated by estrogen and anti-estrogen in hormone-
dependent breast cancer cells. No significant correlation,
however, was observed between PEDF expression and
total ERa status.
PEDF expression is dramatically reduced in endocrine-
resistant breast tumors
Since PEDF expression was dramatically reduced in endo-
crine-resistant breast cancer cells, we next determined
whether there was a clinical correlation between PEDF
expression and the development of endocrine resistance
in breast tumors. PEDF expression was examined in pri-
mary versus recurrence tumors. A total of 209 breast can-
cer patients were initially treated with tamoxifen and
responded; however, 59 patients developed recurrence
disease with an average time to disease progression of 93
months. Immunohistochemical staining was performed
on tissue microarrays constructed using recurrence breast
tumor tissues (n = 59) versus matched primary breast
tumor tissues (n = 59). Figure 2a shows that PEDF protein
was dramatically reduced in the recurrence breast cancer
tissue (right panel) compared with the primary breast
cancer tissue (middle panel) and the normal breast tissue
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(left panel). In particular, we found in the normal breast
tissue and to a lesser extent in the primary breast cancer
tissue that mammary epithelial cells displayed an intense
and widespread staining for PEDF. All of the normal
breast tissue stained positive for PEDF, whereas 68% of
primary tumors were PEDF-positive and 32.2% were
PEDF-negative. In contrast, we found that 47.6% of recur-
rence tumors were PEDF-positive and 52.4% (31 out of
59) of recurrence tumors were PEDF-negative (Table 1).
The number of recurrence tumors that were PEDF-nega-
tive was statistically significantly different from the num-
ber of primary tumors that were PEDF-negative (P <
0.000001) (Table 1). We also examined PEDF expression
in endocrine-responsive tumors (n = 150) to assess
whether PEDF expression correlated with response to
endocrine therapy. We found that ~83.3% of endocrine-
responsive tumors were PEDF-positive and 16.7% were
PEDF-negative, which was significantly different from the
number of recurrence tumors that were PEDF-negative
(P < 0.000001) or PEDF-positive (P < 0.00008) (Table 1).
Overall, these data show that patients who had the worst
response to endocrine therapy (defined as progressive dis-
ease) had significantly lower PEDF expression than those
who had the best response to endocrine therapy (defined
as complete response) and that poor clinical response to
endocrine therapy is associated with PEDF deficiency in
primary breast carcinomas. Notably, Cai and colleagues
previously reported that PEDF expression was signifi-
cantly reduced in breast cancer tissues compared with
normal breast tissue [24]; however, these investigators did
not examine whether PEDF expression correlated with
response to endocrine therapy or acquired resistance.
Since loss of ERa has been shown to be associated with
the development of endocrine resistance in breast cancer,
we assessed ERa status in the primary tumors versus the
recurrence tumors using immunohistochemistry. We
Figure 1 Pigment epithelium-derived factor expression in human breast cancer cell lines. (a) Pigment epithelium-derived factor (PEDF)
and estrogen receptor alpha (ERa) protein levels were detected by western blot analysis in several human breast cancer cell lines, including
hormone-dependent T47D, MCF-7, and ZR-75-1 cells, tamoxifen-resistant BT474 cells, tamoxifen-resistant and aromatase inhibitor-resistant MCF-
7:5C and MCF-7:2A cells, and ER-negative MDA-MB-231 cells. (b) PEDF mRNA expression level in the different breast cancer cell lines was
determined by quantitative real-time PCR analysis with PUM1 used as a normalization control. (c) Conditioned media were analyzed by western
blot for the presence of PEDF protein in the indicated breast cancer cell lines. Staining of proteins by Coomassie blue included as a loading
control. (d) Hormonal regulation of PEDF and ERa protein in MCF-7 and T47D breast cancer cells. Cells were incubated in phenol red-free RPMI
media supplemented with 10% charcoal-stripped FBS for 72 hours and, subsequently, were treated with vehicle, 1 nM 17b-estradiol (E2), or 1 nM
E2 + 1 μM 4-hydroxytamoxifen (4OHT) for 24 hours, and the PEDF and ERa protein level was determined by western blot analysis. b-actin was
used as a normalization control. All experiments were performed in triplicate independently.
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Figure 2 Pigment epithelium-derived factor expression in primary and recurrence breast tumor tissues. (a) Immunohistochemistry (IHC)
staining for pigment epithelium-derived factor (PEDF) and estrogen receptor alpha (ERa) were performed on tissue microarrays generated from
normal breast tissue (left panel), primary breast tumor tissue (n = 59; middle panel), and recurrence breast tumor tissue (n = 59; right panel).
Cores used to generate tissue microarrays (TMAs) were 0.6 mm in diameter. Tumor tissues were also stained in the absence of a PEDF antibody
to act as a negative control (left panel, inset). PEDF staining was quantified as an intensity score ranging from 0 to 255. A scale of 0 to 3 was
used to score staining intensity of ERa. (b) Western blot analysis of normal tissue (N), primary breast tumor tissue (PT), or recurrence tumor
tissue (RT) to assess PEDF, total ERa, and phosphorylated ERa (Ser118 and Ser167) protein level. b-actin was used as a loading control.
(c) Representative quantitative real-time PCR analysis of PEDF and ERa mRNA expression in N, PT, or RT. For experiment, total RNA was extracted
from paraffin-embedded tissues using Trizol and analyzed by real-time PCR as described in Materials and methods. PEDF and ERa mRNA were
normalized to the internal control gene PUM1. All experiments were performed in triplicate. PEDF mRNA level was statistically significantly lower
in the recurrence tumor tissue compared with the primary tumor tissue. *P < 0.001.
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found that ERa protein was expressed at high levels (+3) in
both the primary and the recurrence tumors and that there
was no significant difference in ERa expression between the
primary versus the recurrence tumors (Figure 2a). Western
blot and real-time PCR analyses were also performed on the
primary and recurrence breast tumor tissues to determine
PEDF and ERa protein and the mRNA status. Figure 2b
shows that the PEDF protein level was markedly reduced in
the recurrence tumors compared with the primary tumors;
however, the total ERa protein level was similar between
the two groups with a similar trend observed for PEDF
mRNA and ERa mRNA (Figure 2c). We should note that
while the total ERa expression level was similar in the pri-
mary tumors versus the recurrence tumors, pser167ER pro-
tein was markedly elevated in the recurrence tumors versus
the primary tumors.
PEDF silencing confers resistance to tamoxifen in breast
cancer cells and its stable expression sensitizes resistant
cells to endocrine therapy
To establish a causal connection between PEDF expres-
sion and endocrine resistance, we explored the functional
consequences of PEDF silencing on tamoxifen sensitivity
in endocrine-sensitive MCF-7 and T47D breast cancer
cells. Cells were transiently transfected with either PEDF
siRNA or nontarget control siRNA for 72 hours and PEDF
silencing was quantified by western blot and quantitative
RT-PCR analyses. As shown in Figure 3a (top panel),
PEDF siRNA dramatically reduced PEDF protein and
mRNA levels in both MCF-7 and T47D cells compared
with the nontarget control siRNA. PEDF knockdown cells
were then treated with 1 μM 4OHT, the active metabolite
of tamoxifen, and cell growth was determined after 72
hours using a DNA proliferation assay kit. As shown in
Figure 3a (middle panel), PEDF silencing significantly (P <
0.01) reduced the sensitivity of MCF-7 and T47D cells to
4OHT compared with cells transfected with the nontarget
control siRNA. Specifically, we found that 1 μM 4OHT
inhibited the growth of MCF-7 and T47D cells transfected
with the nontarget control siRNA by 92% and 87%,
respectively, whereas 4OHT reduced the growth in PEDF-
knockdown MCF-7 and T47D cells by 45.6% and 54%,
respectively. PEDF-knockdown MCF-7 and T47D cells
were also treated with 1 μM 4OHT for 72 hours and cell
proliferation was determined by counting viable cells
using trypan blue exclusion. Figure 3a (bottom panel)
showed that 4OHT reduced the proliferation of MCF-7
and T47D cells transfected with the control siRNA by ~85
to 90%; however, in the PEDF knockdown cells, the ability
of 4OHT to inhibit proliferation was significantly reduced
compared with 4OHT-treated cells transfected with the
control siRNA (P < 0.01).
Since MCF-7:5C and BT474 breast cancer cells are
resistant to tamoxifen and they express low levels of
PEDF, we next examined whether stable expression of
PEDF in these cells would sensitize them to the inhibi-
tory effects of tamoxifen. We used a lentiviral construct
encoding the full-length human PEDF cDNA to stably
express PEDF in MCF-7:5C and BT474 cells. The effi-
ciency of PEDF lentiviral transduction of MCF-7:5C and
BT474 cells was confirmed by western blot analysis. As
shown in Figure 3b (top panel), PEDF expression was
very high in the lentiviral transduced cells, 5C-PEDF and
BT474-PEDF, compared with the untransduced cells,
MCF-7:5C and BT474. Following confirmation of PEDF
overexpression, transduced 5C-PEDF and BT474-PEDF
cells were treated with 10-12 to 10-6 M of 4OHT for 7
days and cell growth was determined using a DNA quan-
titation assay. As shown in Figure 3b (middle panel),
4OHT treatment reduced the growth of transduced 5C-
PEDF and BT474-PEDF cells in a dose-dependent man-
ner with maximum inhibition at 100 nM compared with
Table 1 Pigment epithelium-derived factor expression in normal versus breast tumor tissue samples
Tissue sample n PEDF status Intensity score
Recurrence tumors 28 (47.6%)a Positive > 150
31 (52.4%)b Negative ≤ 25
Primary tumors 40 (67.8%)a Positive > 150
19 (32.2%)b Negative ≤ 25
Endocrine-responsive tumors 125 (83.3%)c Positive > 150
25 (16.7%)d Negative ≤ 25
Normal tissue 5 (100%) Positive ≥ 200
0 (0%) Negative ≤ 25
A total of 209 breast cancer patients were initially treated with tamoxifen and 59 patients developed recurrence disease after a mean follow-up of 93 months.
Immunohistochemistry (IHC) staining was performed on tissue microarrays (TMAs) constructed from recurrence breast tumors (n = 59) and matched primary
breast tumors (n = 59). Normal background breast tissue was also used for comparison. TMAs were also constructed from endocrine-responsive tumor tissues
(n = 150). A semi-automated quantitative image analysis system (ACIS II) was used to quantitate the staining of the TMA slides. For IHC analysis, pigment
epithelium-derived factor (PEDF) staining was quantified as an intensity score (scale 0 to 255). aP < 0.00003, number of PEDF-positive recurrence tumors versus
PEDF-positive primary tumors. bP < 0.000001, number of PEDF-negative recurrence tumors versus PEDF-negative primary tumors. cP < 0.00008, number of PEDF-
positive recurrence tumors versus PEDF-positive endocrine-responsive tumors. dP < 0.000001, number of PEDF-negative recurrence tumors versus PEDF-negative
endocrine-responsive tumors.
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untransduced MCF-7:5C and BT474 cells that showed no
response to 4OHT at any of the concentrations tested.
We confirmed that the inhibitory effect of 4OHT in 5C-
PEDF and BT474-PEDF cells was due to a reduction in
cell proliferation/viability as determined by trypan blue
exclusion and that the re-expression of PEDF in MCF-
7:5C and BT474 cells significantly (P < 0.05) enhanced
their sensitivity to 4OHT compared with the untrans-
duced cells (Figure 3b, bottom panel).
Effect of PEDF expression on ERa signaling in endocrine-
resistant MCF-7:5C cells
Since our tissue microarray data showed increased
expression of pSer167ERa in endocrine-resistant tumors
that expressed low levels of PEDF, we examined the
effect of PEDF re-expression on ERa signaling in endo-
crine-resistant MCF-7:5C cells that are PEDF-negative.
We found that stable expression of PEDF in MCF-7:5C
cells (5C-PEDF) dramatically reduced the protein levels
of ERa, pSer167ERa, pAKT, and the proto-oncogenic
receptor tyrosine kinase RET, which were constitutively
elevated in the untransduced MCF-7:5C cells but not
parental MCF-7 cells (Figure 4a). Furthermore, we
found that treatment of MCF-7:5C cells with 100 nM
rPEDF markedly reduced the phosphorylation level of
ERa and RET protein in these cells (Figure 4b) and it
significantly reduced ERa transcriptional activity in
these cells (Figure 4c). In particular, we found that basal
Figure 3 Knockdown of pigment epithelium-derived factor expression by siRNA reduces tamoxifen sensitivity in breast cancer cells.
(a) siRNA-mediated reduction of pigment epithelium-derived factor (PEDF) expression in MCF-7 and T47D breast cancer cells was performed as
described in Materials and methods. Cells were transfected with PEDF or control siRNA for 72 hours and PEDF protein and mRNA levels were
determined by western blot and real-time PCR analyses. Transfected cells were also treated with 1 μM 4-hydroxytamoxifen (4OHT) for 72 hours
and cell proliferation was determined by DNA quantitation assay and by cell counting using trypan blue exclusion. All experimental points are
given as the average of triplicates. (b) Stable expression of PEDF in endocrine-resistant MCF-7:5C and BT474 breast cancer cells sensitized them
to tamoxifen. A lentiviral construct encoding the human PEDF cDNA was used to stably express PEDF in MCF-7:5C and BT474 cells. Western blot
analysis was used to confirm stable expression of PEDF protein in MCF-7:5C and BT474 cells (top panel). To determine the effect of PEDF
expression on tamoxifen sensitivity, lentiviral transduced 5C-PEDF and BT474-PEDF cells were treated with 10-12 M to 10-6 M 4OHT for 72 hours
and cell proliferation was determined by DNA quantitation assay (middle panel) and by cell counting using trypan blue exclusion (bottom
panel). All experimental points are given as the average of triplicates. Assays were performed twice.
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Figure 4 Effect of recombinant pigment epithelium-derived factor on the estrogen receptor alpha signaling pathway. (a) Western blot
analysis of pigment epithelium-derived factor (PEDF), estrogen receptor alpha (ERa), phospho-ER, phospho-Akt, mitogen-activated protein kinase
(MAPK), phospho-MAPK, rearranged during transfection (RET), pRET, p70S6K, and mammalian target of rapamycin (mTOR) protein expression in
MCF-7, MCF-7:5C, and 5C-PEDF cells. (b) Effect of recombinant PEDF on ERa, pERa, RET, and pRET (Y1062) protein expression in MCF-7:5C cells.
Cells were treated with 100 nM recombinant PEDF (rPEDF) protein for 24 hours and cell lysates were analyzed by western blot. b-actin was used
as a loading control. (c) Effect of rPEDF on estrogen response element (ERE) luciferase activity in MCF-7 and MCF-7:5C cells. MCF-7 and MCF-7:5C
cells were grown in estrogen-free RPMI media and then co-transfected with a 5× ERE luciferase plasmid and a renilla reporter plasmid for
24 hours. Following transfection, cells were treated with 1 nM 17b-estradiol (E2), 100 nM rPEDF, or E2 + rPEDF for 24 hours and luciferase activity
was measured. Values presented as relative luciferase activity after normalization to Renilla luciferase activity. Data expressed as mean ± standard
deviation of the results obtained from triplicate experiments. Basal ERE activity was statistically significantly higher in MCF-7:5C cells compared
with MCF-7 cells. *P < 0.01.
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ERE luciferase activity was significantly higher (~3.3-
fold) in endocrine-resistant MCF-7:5C cells compared
with endocrine-sensitive MCF-7 cells and treatment
with rPEDF completely suppressed the basal ERE activ-
ity in MCF-7:5C cells and it significantly reduced
E2-induced ERE activity in these cells (Figure 4c). Note-
worthy is that pAKT and RET are known to enhance
phosphorylation of ERa at Ser118 and Ser167, which is
associated with increased ERa transcriptional activity
and tamoxifen resistance [36]. The fact that stable
expression of PEDF and the administration of rPEDF
protein in MCF-7:5C cells was able to suppress pSer167-
ERa, p-AKT, and RET expression suggests a potential
crosstalk between PEDF, ERa and RET in these cells.
This finding highlights a potential mechanism by which
silencing/loss of PEDF might contribute to the develop-
ment of resistance in MCF-7:5C cells. We should note
that re-expression of PEDF in BT474 cells did not sig-
nificantly alter ERa phosphorylation status or RET
expression in these cells; however, it did slightly reduce
HER2 expression in these cells (data not shown).
Downregulation of RET reverses tamoxifen resistance in
MCF-7:5C breast cancer cells
Previous studies have shown that a subset of ERa-positive
breast cancers express high levels of mRNA transcripts
encoding RET and that RET signaling in ERa-positive
breast cancer cell lines can result in the activation of
MAPK and AKT, which are important regulators of ERa
phosphorylation [43,44]. More recently, RET signaling has
been implicated in estrogen-independent growth and
tamoxifen resistance in breast cancer, potentially through
ERa phosphorylation and ligand-independent transcrip-
tional regulation [43-45]. Since our data showed that
re-expression of PEDF suppressed RET, ERa and AKT in
endocrine-resistant MCF-7:5C cells, we examined the
biological effect of RET in endocrine-sensitive MCF-7
breast cancer cells and estrogen-independent and tamoxi-
fen-resistant MCF-7:5C cells. As shown in Figure 5a, RET
protein and mRNA levels were markedly increased in
endocrine-resistant MCF-7:5C cells compared with MCF-
7 cells. Transfection of MCF-7:5C cells with RET siRNA
completely downregulated RET protein and mRNA levels
(Figure 5b) in these cells. Dose-response survival curves
performed over a range of 4OHT concentrations from
10-9 to 10-6 M confirmed that the untreated and siRNA
control-treated MCF-7:5C cells were indeed resistant to
4OHT treatment (Figure 5c). In contrast, RET downregu-
lation resulted in a profound increase in sensitivity to
4OHT (Figure 5c). These results indicate that there might
be potential crosstalk between PEDF, RET, and ERa sig-
naling pathways and that RET targeting might be a viable
strategy to resensitize resistant breast cancers to endocrine
therapy.
PEDF inhibits endocrine-resistant breast cancer cell
growth in vitro and exhibits anti-tumor activity in vivo
Although our studies have shown that PEDF is capable of
modulating ERa and RET signaling pathways in endo-
crine-resistant breast cancer cells, it is worth noting that
the most well-known function of PEDF is its ability to
inhibit angiogenesis. We therefore examined the effect of
rPEDF on the proliferation of endocrine-sensitive MCF-7
and endocrine-resistant MCF-7:5C breast cancer cells. As
shown in Figure 6a, rPEDF significantly (P < 0.001)
reduced the growth of resistant MCF-7:5C cells but had
no effect on parental MCF-7 cells. The growth-inhibitory
effect of rPEDF was concentration dependent, with maxi-
mum inhibition (~90%) observed at 100 nM, and this inhi-
bitory effect of rPEDF was completely blocked by the
addition of antibodies specific to PEDF, thus confirming
that the effect of PEDF was specific. To determine whether
the anti-proliferative effect of rPEDF on MCF-7:5C cells
was due to apoptosis, we next performed a TUNEL assay.
Figure 6b showed that rPEDF (100 nM) markedly
increased apoptosis in MCF-7:5C cells, with 41.8% of cells
being TUNEL-positive, compared with the untreated (con-
trol) cells that showed very few TUNEL-positive cells.
Because rPEDF treatment caused endocrine-resistant
MCF-7:5C cells to undergo apoptosis, we also examined
whether knockdown of PEDF expression in MCF-7 cells
would cause them to undergo apoptosis. We found that
PEDF knockdown in MCF-7 cells did not inhibit the
growth of these cells or cause them to undergo apoptosis
in the presence of rPEDF (data not shown), thus confirm-
ing that the ability of rPEDF to induce apoptosis is specific
for MCF-7:5C cells.
Since rPEDF was shown to effectively inhibit the growth
of endocrine-resistant MCF-7:5C breast cancer cells in
vitro, we next evaluated the effect of rPEDF on MCF-7:5C
tumor growth in vivo. Endocrine-resistant MCF-7:5C
breast cancer cells were injected subcutaneously into the
mammary fat pads of ovariectomized nude mice. When
palpable tumors were established (0.1 cm2), the animals
were randomized into two groups and then treated with
either rPEDF (4 mg/kg) or PBS vehicle control that was
administered every 2 days by intraperitoneal injection. We
found that rPEDF reduced the growth of MCF-7:5C
tumors at all of the time points examined. The average
tumor area was reduced from 0.42 cm2 in the PBS-treated
group to 0.12 cm2 in the rPEDF-treated group (Figure 6c).
The differences between the two groups were statistically
significant (P < 0.001), as calculated by repeated-measures
analysis of variance. We next determined whether the
anti-tumor activity of rPEDF in vivo was due, in part, to its
ability to inhibit angiogenesis. For this purpose, MCF-7:5C
xenografts were excised at the end of the experiment (day
30) and were sectioned and analyzed by immunohisto-
chemistry using antibody to CD34, a well-known marker
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for newly formed blood vessels/angiogenesis. As shown in
Figure 6d (top), tumors from mice treated with PBS
showed intense staining for CD34, indicating the presence
of extensive angiogenesis in the tumors, whereas micro-
vessel density in tumors from mice treated with rPEDF
was markedly lower. A 48% reduction in microvessel den-
sity was observed in the rPEDF-treated group compared
with the PBS-treated group (P < 0.01; Figure 6d, bottom
panel). These data demonstrate that rPEDF is capable of
inhibiting the neovascularization of endocrine-resistant
breast carcinoma in vivo.
PEDF expression sensitizes endocrine-resistant MCF-7:5C
tumors to tamoxifen
Since our in vitro data showed that stable expression of
PEDF in endocrine-resistant MCF-7:5C cells sensitized
them to tamoxifen, we examined whether rPEDF is cap-
able of sensitizing endocrine-resistant MCF-7:5C tumors
to tamoxifen in athymic mice. Figure 7a shows that the
growth of MCF-7:5C tumors was significantly reduced by
rPEDF alone (P < 0.0001) but not by tamoxifen alone;
however, when rPEDF and tamoxifen were combined the
growth of MCF-7:5C tumors was significantly reduced
compared with rPEDF alone (P < 0.01) (Figure 7a). For
comparison, we also performed similar experiments using
MCF-7 and BT474 tumors. We found that MCF-7 tumor
growth was significantly inhibited by tamoxifen (P <
0.0001) and rPEDF (P < 0.01); however, the combination
of tamoxifen and rPEDF did not further reduce the growth
of these tumors compared with the individual treatments
(Figure 7b). BT474 tumor growth was also significantly
inhibited by rPEDF alone (P < 0.001) and the combination
of rPEDF and tamoxifen (P < 0.05), but tamoxifen alone
had no effect (Figure 7c). We next investigated whether
ERa and other signaling proteins were altered in MCF-
7:5C tumors treated with rPEDF, tamoxifen, or rPEDF and
tamoxifen. Western blot analysis of MCF-7:5C tumor
extracts showed that pSer167ERa, p-Akt, and p-RET pro-
tein were markedly reduced in the rPEDF-treated and
rPEDF plus tamoxifen-treated samples compared with
control or tamoxifen-treated samples (Figure 7d), which is
consistent with our in vitro data. Overall, these results sug-
gest that rPEDF is capable of inhibiting the growth of
endocrine-sensitive MCF-7 tumors as well as endocrine-
resistant MCF-7:5C and BT474 tumors, possibly through
its anti-angiogenic activity; however, rPEDF is also capable
Figure 5 Knockdown of RET mRNA expression sensitizes endocrine-resistant MCF-7:5C breast cancer cells to 4-hydroxytamoxifen.
(a) Rearranged during transfection (RET) protein and mRNA levels in wild-type MCF-7 cells and endocrine-resistant MCF-7:5C cells as determined
by western blot analysis and quantitative real-time PCR, respectively. (b) MCF-7:5C cells were transfected with either a RET-targeted siRNA or a
nontarget control siRNA for 48 hours and RET protein and mRNA expression levels were determined by western blotting and real-time PCR.
(c) Effect of RET suppression on the proliferation of MCF-7:5C cells. Cells were transfected with a RET-targeted or a nontargeting control siRNA,
and after 24 hours cells were seeded into 12-well plates and exposed continuously to the indicated concentrations of 4-hydroxytamoxifen
(4OHT) or vehicle for an additional 72 hours. Cell proliferation was determined by cell counting using a hemacytometer. Data shown are
representative of three independent experiments. UT, untreated.
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of sensitizing MCF-7:5C tumors to tamoxifen, which
appears to be associated with its ability to downregulate
phosphorylated ERa, Akt, and RET in these tumors.
Discussion
Resistance to endocrine therapy presents a major chal-
lenge in the management of ERa-positive breast cancer
and is an area under intense investigation. While many
studies point towards the cross-talk between ERa and
growth factor receptor signaling pathways as the key in
the development of resistance [5,6,46,47], the underlying
mechanism is still not fully understood and, as a conse-
quence, effective approaches for preventing and over-
coming resistance are not yet available. PEDF is a
secreted glycoprotein that was first described in the late
1980s after it was identified and isolated from condi-
tioned medium of cultured primary human fetal retinal
pigment epithelial cells [8]. PEDF is ubiquitously
expressed in many tissues and possesses potent anti-
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Figure 6 Effect of recombinant pigment epithelium-derived factor (rPEDF) on the growth of endocrine-sensitive MCF-7 and endocrine-
resistant MCF-7:5C breast cancer cells in vitro and in vivo. (a) MCF-7 and MCF-7:5C cells were treated with increasing concentrations of
rPEDF, rPEDF + anti-PEDF antibody (anti-PEDF), or anti-PEDF antibody for 7 days, and cell proliferation was determined using a DNA quantitation
kit as described in Materials and methods. Experiments were repeated three times, and data are shown as mean ± standard deviation (SD). *P <
0.001 compared with untreated controls. (b) MCF-7:5C cells were treated with rPEDF, anti-rPEDF, or rPEDF + anti-rPEDF for 72 hours and
apoptosis was determined by TUNEL staining. Bar graph: summary of percentage of apoptotic cells counted in five fields from three
experiments. Data presented as mean ± SD. (c) Effect of rPEDF on the growth of MCF-7:5C cells in vivo. MCF-7:5C cells were bilaterally injected
into the mammary fat pad of ovariectomized nude mice, and when tumors reached an area of 0.1 cm2 the mice (n = 15/group) were
randomized into two treatment groups: PBS or rPEDF. The mean cross-sectional tumor area was measured up to 30 days. Bar graph: mean cross-
sectional tumor area in the control group and the PEDF-treated group. (d) Intratumoral microvessel density (MVD) in tumor tissues was
determined by immunohistochemical staining by an endothelial-specific antibody CD34; PBS group (×200) and PEDF group (×200). Quantitative
analysis of microvessel density is also shown. Data presented as mean ± SD.
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angiostatin and more than seven times as potent as endo-
statin [12]. Recent studies indicate that PEDF expression
is significantly reduced in a wide range of tumor types
and that its re-expression in these tumors delays the
onset of primary tumors and decreases metastases [48].
In the present study, we show that loss of PEDF expres-
sion in breast cancer is associated with the development
of endocrine resistance and that there is functional cross-
talk between PEDF and the ERa signaling pathway.
Specifically, we found that PEDF protein and mRNA
levels were markedly reduced in tamoxifen-resistant
breast tumors and in breast cancer cells that are resistant
to AIs and/or tamoxifen. We also found that stable re-
expression of PEDF in the resistant cells re-sensitized
them to the antiproliferative effects of tamoxifen and that
re-expression of PEDF dramatically reduced the expres-
sion of the receptor tyrosine kinase RET along with
p-AKT and pSer167ERa. Furthermore, we found that exo-
genous administration of rPEDF significantly inhibited
the growth of endocrine-resistant breast cancer cells in
vitro and in vivo but had no effect on the growth of endo-






































































































































Figure 7 Effect of recombinant pigment epithelium-derived factor on tamoxifen sensitivity in MCF-7:5C, MCF-7, and BT474 xenografts.
(a) MCF-7:5C cells were bilaterally injected into the mammary fat pads of ovariectomized athymic mice (n = 32), and after tumors reached a
mean cross-sectional area of 0.2 cm2 groups of eight mice were randomly assigned to the following treatments: PBS (control), recombinant
pigment epithelium-derived factor (rPEDF), tamoxifen (TAM), or rPEDF + TAM. TAM was given orally by gavage at 1.5 mg/day and rPEDF was
given via intraperitoneal injection at 4 mg/kg every other day for 21 days. (b) MCF-7 cells were bilaterally injected into the mammary fat pads of
ovariectomized mice (n = 32), and after tumors reached a mean cross-sectional area of 0.32 cm2 groups of eight mice were randomly assigned
to the following treatments: PBS (control), rPEDF, TAM, or rPEDF + TAM as described in Materials and methods. (c) BT474 cells were bilaterally
injected into the mammary fat pads of ovariectomized mice (n = 32), and after tumors reached a mean cross-sectional area of 0.3 cm2 groups of
eight mice were randomly assigned to the following treatments: PBS (control), rPEDF, TAM, or rPEDF + TAM. Mean cross-sectional tumor area
was measured every 5 days with vernier calipers. Cross-sectional areas were calculated by multiplying the length (l) by the width (w) and by π
and dividing the product by 4 (that is, lwπ/4). (d) Western blot analysis of MCF-7:5C tumors following treatment with rPEDF, tamoxifen, or rPEDF
and tamoxifen. Tumors were generated as described in 7a and the lysates were preprepared as described in Materials and Methods. Blots were
probed with the indicated antibodies.
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effect in vivo. While PEDF is known to exert anti-tumor
activity by inhibiting angiogenesis [49,50] and inducing
apoptosis [17], the present study is the first to demon-
strate a link between loss of PEDF expression and the
development of endocrine resistance and to show that
PEDF re-expression is capable of reversing tamoxifen
resistance in breast cancer.
During the past decade, researchers have prepared var-
ious forms of PEDF and demonstrated its beneficial effects
in several tumor models. Doll and colleagues reported that
exogenous rPEDF protein induced tumor epithelial apop-
tosis in mouse prostate and pancreas [13]. Liu and collea-
gues showed that a short peptide derived from the parent
PEDF molecule was able to inhibit osteosarcoma growth
[51]. Hase and colleagues demonstrated that intratumoral
injection of a lentivirus vector encoding PEDF resulted in
inhibition of human pancreatic cancer in nude mice [52].
Moreover, Wang and colleagues showed that in vivo trans-
fer of PEDF mediated by adenoviral vectors exerted a dra-
matic inhibition of tumor growth in athymic nude mice
implanted with the human HCC and in C57BL/6 mice
implanted with mouse lung carcinoma [53]. In the present
study we showed that exogenous rPEDF preferentially
induced apoptosis in endocrine-resistant MCF-7:5C and
BT474 breast cancer cells compared with endocrine-sensi-
tive MCF-7 cells and that rPEDF partially reversed the
tamoxifen-resistant phenotype of MCF-7:5C and BT474
cells in vitro and in vivo. Interestingly, we found that lenti-
viral-mediated re-expression of PEDF in the resistant cells
also reversed tamoxifen resistance in these cells. Investiga-
tion into the mechanism of action of PEDF in the resistant
cells indicated that the anti-tumor activity of PEDF in vivo
was due, in part, to its ability to inhibit angiogenesis, as
was demonstrated by a reduction in microvessel density
and an increase in apoptosis. Interestingly, we found that
exogenous PEDF failed to induce apoptosis in MCF-7
breast cancer cells in vitro; however, it significantly inhib-
ited the growth of MCF-7 tumors in athymic mice, which
was due to its anti-angiogenic activity. The anti-tumor
activity of PEDF, however, was more pronounced in the
endocrine-resistant breast cancer cells compared with the
endocrine-sensitive cells. We should note that a similar
finding was reported by Konson and coworkers in which
they showed that exogenous PEDF preferentially induced
apoptosis in endothelial cells compared with MDA-MB-
231, HCT116, and U87-MG cancer cells [54,55]; however,
PEDF efficiently inhibited the growth rate of xenografts
generated from these cancer cells. While the reason for
this cell-type specific effect of PEDF is not known, there is
evidence for multiple PEDF receptors at the cell surface
including the recently identified non-integrin 67/37-kDa
laminin receptor [56], extracellular matrix components
[57], and a phospholipase-linked membrane protein [58].
Differential expression of these receptors on neuronal,
endothelial, and cancer cells may provide a partial expla-
nation for the differential effects on these cell populations.
Identification of which of these PEDF receptors are
present on cancer cells, as well as further elucidation of
signaling downstream of PEDF, could lead to the identifi-
cation of new pharmacologic targets for both anti-cancer
and neuronal survival therapies. We are currently trying to
determine whether there is a specific PEDF receptor
expressed in breast cancer cells and whether the functional
activity of the receptor is altered by the endocrine respon-
siveness of the cells.
Apart from its ability to inhibit to angiogenesis, we also
found that PEDF suppressed RET expression in endo-
crine-resistant breast cancer cells and that this suppression
was associated with the reversal of tamoxifen resistance.
Specifically, we found that basal RET, p-RET, ERa, and
pSer167-ERa protein levels were markedly increased in
endocrine-resistant MCF-7:5C cells compared with endo-
crine-sensitive MCF-7 cells and stable expression of PEDF
in MCF-7:5C cells or treatment of these cells with rPEDF-
suppressed RET, p-RET, and pSer167-ERa protein in these
cells. Furthermore, we found that suppression of RET
expression using siRNA knockdown also reversed tamoxi-
fen resistance in MCF-7:5C cells, which suggests a role for
RET in tamoxifen resistance. This finding is important
because recent studies have indicated that RET is involved
in the biology of ERa-positive breast cancers [43,44] and
in the response to endocrine treatment [45]. Two indepen-
dent studies have identified RET overexpression in a sub-
set of ERa-positive breast cancers [43,44], suggesting an
important role of RET in this subset. By in situ hybridiza-
tion, in a cohort of 245 invasive breast cancers, RET
mRNA was detected in 29.7% of the tumors and preferen-
tially expressed in ER-positive cases. Subsequent studies in
the same cohort of patient samples corroborated that
increased RET mRNA levels correlated with increased
RET protein expression. Similar findings were reported for
many breast cancer cell lines where RET expression corre-
lated strongly with ERa expression and/or ErbB2/HER2
overexpression [43].
RET is a receptor tyrosine kinase protein of 150 kDa
that is expressed and required during early development
for the formation of neural crest-derived lineages, kidney
organogenesis, and spermatogenesis [59]. RET is consid-
ered the driving oncogene in various neoplasms of the
thyroid, where specific mutations lead to defined tumor
types [60-62]. The RET protein spans the cell membrane,
so that one end of the protein remains inside the cell and
the other end projects from the outer surface of the cell.
This positioning of the protein allows it to interact with
specific factors outside the cell and to receive signals that
help the cell respond to its environment. When molecules
that stimulate growth and development such as growth
factors attach to the RET protein, a complex cascade of
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chemical reactions inside the cell is triggered. These reac-
tions instruct the cell to undergo certain changes, such as
dividing or maturing to take on specialized functions. RET
is the receptor for a family of glial-derived neurotrophic
factor (GDNF) ligands, which includes GDNF, artemin,
neurturin, and persephin [60,63]. These ligands bind RET
in conjunction with glycosylphosphatidylinositol-anchored
co-receptors of the GDNF receptor alpha family, and the
ligand-co-receptor-RET complex formation results in
transient RET dimerization and activation of the RET tyr-
osine kinase domain. RET protein dimerization results in
autophosphorylation of several intracellular RET tyrosine
residues, and these autophosphorylation sites serve as
binding sites for a variety of docking proteins. In particu-
lar, the tyrosine Y1062 has been shown to bind Src homol-
ogy and collagen, insulin receptor substrate1/2, fibroblast
growth factor receptor substrate 2, and protein kinase C
alpha. These proteins are able to activate multiple signal-
ing pathways, including MAPK, PI3K/AKT, RAS/extracel-
lular signal-regulated kinase and Rac/c-jun NH kinase,
which are mediators of cell motility, proliferation, differen-
tiation, and survival [64]. While our present study indi-
cates that PEDF is capable of suppressing RET signaling in
endocrine-resistant cells, we do not know the exact
mechanism by which this occurs. We should note that
RET is the receptor for several ligands including GNDF,
which is a potent neurotropic factor similar to PEDF. Like
other trophic factors, PEDF is thought to exert its biologi-
cal effects by specifically binding and activating one or
more receptors. While PEDF receptors have not yet been
fully characterized, there is a possibility that PEDF, like
GDNF, is able to bind to RET and thus regulate its expres-
sion and activity in breast cancer cells. This possibility is
currently being investigated in our laboratory.
RET and other growth factor receptor tyrosine kinases are
known to activate ERa through phosphorylation [36]. The
ERa contains two distinct transcription activation domains,
AF-1 and AF-2, which can function independently or syner-
gistically. AF-2 is located in the ligand-binding domain
region of ERa and its activity is dependent on estrogen
binding, whereas AF-1 activity is regulated by phosphoryla-
tion that can occur independently of estrogen binding [5].
The extracellular signal-regulated kinase 1/2 pathway phos-
phorylates ERa directly and/or via p90RSK, whereas AKT
phosphorylates ERa directly and/or via mTOR. In contrast,
RET increases ERa phosphorylation at Ser118 and Ser167
through activation of the mTOR/p70S6K pathway
[43,59,65], which can be independent of the PI3K/AKT
pathway. Notably, p70S6K, mTOR, and p-AKT were also
constitutively overexpressed in endocrine-resistant MCF-
7:5C cells prior to stable expression of PEDF in these cells.
In addition, basal ERa transcriptional activity, as deter-
mined by ERE luciferase assay, was significantly elevated in
MCF-7:5C cells compared with wild-type MCF-7 cells, and
treatment of these cells with rPEDF inhibited phosphoryla-
tion of ERa and RET and suppressed the basal ERE activity
in these cells. Interestingly, we found that suppression of
RET expression using siRNA and inhibition of the mTOR
pathway using rapamycin was able to reverse tamoxifen
resistance in MCF-7:5C cells; however, inhibition of the
PI3K/AKT pathway in these cells did not reverse their
tamoxifen-resistant phenotype but it did reduce their hor-
mone-independent growth. Notably, crosstalk between RET
and ERa has previously been reported by Plaza-Menacho
and coworkers, who showed that activation of RET by its
ligand GDNF increased ERa phosphorylation on Ser118
and Ser167 and increased estrogen-independent activation
of ERa transcriptional activity [45]. Further, they identified
mTOR as a key component in this downstream signaling
pathway and they showed in tamoxifen-resistant (TAMR-1)
MCF-7 cells that targeting RET restored tamoxifen
sensitivity.
Conclusion
In summary, we have found that PEDF expression is
markedly reduced in endocrine-resistant breast cancer and
that stable expression of PEDF in endocrine-resistant cells
restores their sensitivity to tamoxifen by suppressing RET
and ERa signaling. The ability of PEDF to suppress RET
signaling in endocrine-resistant cells is a newly identified
function of PEDF that is independent of its most well-
known function as a potent endogenous anti-angiogenic
factor. This finding suggests that PEDF expression in
breast cancer might be an important marker of endocrine
responsiveness and that loss of PEDF might be a potential
hallmark for the development of endocrine resistance. The
fact that PEDF is endogenously produced and is widely
expressed throughout the body reduces the likelihood that
it will have adverse side effects like other synthetic agents
or develop drug resistance. However, we should caution
that relatively little is known of the overall physiologic role
of PEDF in the human body; hence, further investigation
is required before any clinical trial can be initiated.
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